iiinova — where your digital self keeps evolving

Reposted by Catherine Mezzacappa

Oren Fix @orenfix.bsky.social · 17/08/2025

We’re proposing a Clinical Informatics & Digital Health SIG to bring together members interested in EHR optimization, AI, clinical decision support, data science, mentorship & more. 👉 If the SIG is approved, would you join? Send me a chat for details! #AASLD

033

Catherine Mezzacappa @mezzc.bsky.social · 05/08/2025

How do we translate novel steatotic liver disease definitions into usable classifications for clinical research using EMR data? In this study in @aga-cgh.bsky.social we tested 7 different approaches to distinguish MetALD from ALD in Veterans with cirrhosis and compared clinical outcomes.

020

Catherine Mezzacappa @mezzc.bsky.social · 27/07/2025

Wondering what I’m doing wrong (or right?!) that I (human hepatologist) have been asked to review an article about canine brucellosis…

000

Catherine Mezzacappa @mezzc.bsky.social · 14/03/2025

(usually given at age 4-5, ie before school) is not a “booster” (does not need to be timed close to school) but to catch the 5-7% who didn’t respond to the first dose. The second dose can be given sooner as long as it’s 28 days apart. Our pediatrician was very happy to do so for our 3 year old.

000

Catherine Mezzacappa @mezzc.bsky.social · 14/03/2025

As a parent who follows the recommended vaccination schedule I didn’t recall that the first MMR dose is given between 12-15 months of age - so all infants including those who received all recommended vaccines are not protected from measles. I also didn’t know that the second dose

100

Catherine Mezzacappa @mezzc.bsky.social · 14/03/2025

Children get their first dose of MMR at 12-15 months in the routine vaccine schedule - I think most people including parents don’t realize that ALL infants are unprotected until that first dose. The second dose at age 4 is to catch non-responders to the first dose (not a booster), so can give early!

000

Catherine Mezzacappa @mezzc.bsky.social · 16/12/2024

❗️Veterans with both very high cardiometabolic risk and heavy alcohol burden had clinical outcomes closer to MetALD than ALD. ❓Should we be classifying everyone with a certain threshold of alcohol use as ALD regardless of other clinical traits? (4/4)

000

Catherine Mezzacappa @mezzc.bsky.social · 16/12/2024

Classification of SLD varied *dramatically* depending on our choices as investigators. ❗️Beware misclassifying SLD based on absent/missing information about alcohol. ❗️⬆️ triglycerides and ⬇️ HDL are metabolic effects of alcohol use, and can be misleading in classifying SLD (3/4)

100

Catherine Mezzacappa @mezzc.bsky.social · 16/12/2024

Medical records are notoriously bad (biased, non-standardized) at capturing routine alcohol consumption. At the VA, alcohol use is measured annually for all primary care patients. We compared 7 different SLD classification systems with varying alcohol and metabolic risk thresholds. (2/4)

100

Catherine Mezzacappa @mezzc.bsky.social · 16/12/2024

How do we apply the new SLD definitions in research? To study outcomes and implement trials for different SLD subtypes, we first need to be able to accurately identify each clinical entity using medical records/registry data. www.cghjournal.org/article/S154... @amergastroassn.bsky.social

143

Reposted by Catherine Mezzacappa

Andrew Moon @andrewmmoon.bsky.social · 17/11/2024

In the United States, HCC deaths may have plateaued and soon be on the decline due to successful HCV elimination However, persistent increases in MASLD and ALD-related HCC threaten these trends AASLD #TLM24 #Liversky

34813